Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Gynecology | Internal Medicine | Journal

Back to Journal Articles

Stage 1 Hypertension Linked to Increased Risk for ACS in Women

Last Updated: May 17, 2021.

MONDAY, May 17, 2021 (HealthDay News) -- Stage 1 hypertension is associated with an increased risk for acute coronary syndromes (ACS) in women, according to a study published online May 16 in the European Journal of Preventive Cardiology.

Ester Kringeland, M.D., from the University of Bergen in Norway, and colleagues examined associations between stage 1 hypertension and ACS in 12,329 participants in the Hordaland Health Study (mean baseline age, 41 years; 52 percent women). Participants were categorized by baseline blood pressure (BP) category: normotension (BP <130/80 mm Hg), stage 1 hypertension (BP 130 to 139/80 to 89 mm Hg), and stage 2 hypertension (BP ≥140/90 mm Hg).

The researchers found that during 16 years of follow-up, 1.4 and 5.7 percent of women and men, respectively, experienced incident ACS. Stage 1 hypertension was associated with a higher risk for ACS in women after adjustment for diabetes, smoking, body mass index, cholesterol, and physical activity (hazard ratio, 2.18; 95 percent confidence interval, 1.32 to 3.60), while in men, the association was not significant (hazard ratio, 1.30; 95 percent confidence interval, 0.98 to 1.71). Stage 1 diastolic hypertension was associated with ACS in women (hazard ratio, 2.54; 95 percent confidence interval, 1.56 to 4.15) but not in men (hazard ratio, 1.29; 95 percent confidence interval, 1.00 to 1.65), while stage 1 systolic hypertension was not associated with ACS in either sex after additional adjustment for systolic and diastolic BP.

"The results add to emerging evidence indicating that high blood pressure has particularly unfavorable effects on women's hearts," Kringeland said in a statement.

Abstract/Full Text

Previous: Study Shows Disparities in Use of Virtual Orthopedic Services Next: Systemic Reactogenicity Up With Heterologous COVID-19 Vaccine Doses

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion: